Reacción a "Some antidepressants may be more effective than others in the long term"

This is a comprehensive systematic review and network meta-analysis, addressing an important clinical question: whether antidepressants differ in their ability to achieve and maintain improvement in depression over the longer term.

The authors have undertaken a substantial amount of work, including sensitivity analyses examining different study designs, and the findings suggest that there may be differences between individual antidepressants. The press release broadly reflects the findings of the study.

One finding is that continuing antidepressants is associated with a greater likelihood of maintaining improvement compared with discontinuing treatment. Around 62% of those continuing antidepressants maintained improvement, compared with 45% of those switched to placebo. This is broadly consistent with findings from the large ANTLER trial, published in the New England Journal of Medicine, which also found lower rates of relapse in those continuing antidepressants.

However, there are some important qualifications.

 Although the review includes over 30,000 participants, the primary analysis comparing individual antidepressants was based on 35 trials involving approximately 10,000 people. Over half of these trials were judged to be at high risk of bias, and the typical duration of follow-up was around six months. We should therefore be cautious about interpreting these findings as evidence of differences in effectiveness over several years.

A further issue is that the evidence for some individual antidepressants is relatively limited. For example, although bupropion performed less well than several other antidepressants in the network meta-analysis, the primary analysis did not demonstrate a statistically significant difference from fluoxetine, and the evidence for bupropion was based on relatively few participants. The secondary analysis, incorporating additional study designs, suggested a larger difference, but this involves additional assumptions. This illustrates why we should be cautious about translating differences between individual drugs in network meta-analyses into clinical recommendations.

 The authors acknowledge these limitations, and the additional analyses provide some reassurance about the overall findings. Nevertheless, network meta-analysis relies partly on indirect comparisons, and the reliability of individual drug rankings depends on the amount and quality of the underlying evidence.

The study provides useful information to inform treatment decisions, but it cannot tell us which antidepressant will work best for an individual patient. I would not interpret these findings as a reason for someone who is responding well to their current antidepressant to change treatment.

Overall, this is a valuable contribution to the literature, but the findings concerning the relative effectiveness of individual antidepressants should be interpreted cautiously.